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for polymer-free drug delivery in which the drug is contained in a
hollow stent and released through laser drilled holes along the ablu-
minal surface of the stent. We hypothesized that hole-size can
modulate in vivo drug release kinetics from DFS.
METHODS Sterilized DFS (96 mg sirolimus/3.018 mm) with hole di-
ameters of 15, 20 or 25 mm were mounted on a Microtrac Stent De-
livery System and implanted in non-diseased porcine coronary arteries
(target stent-to-artery ratio between 1.10:1 and 1.15:1) for 1 to 90 days
(n¼6/time point). Explanted stents and arteries were analyzed for
sirolimus content using liquid chromatography coupled with ultra
violet detection, and liquid chromatography coupled with tandem
mass spectrometry detection, respectively. Drug release was ﬁt to a bi-
exponential model with zero plateau and tissue content to a mono-
exponential model with the same late half-life as late drug release but
a positive plateau. Bioequivalence analysis was performed following
FDA guidance documentation from 2001 to determine if drug delivery
from DFS with different hole-sizes was statistically different. This
analysis evaluates the ratio of the geometric least square means of test
arms across multiple time points. Test arms are considered bio-
equivalent if their geometric ratio is within the bounds of 0.8 – 1.25.
RESULTS Sirolimus release kinetics from DFS were biexponential (Fig
A, R2>0.99), speaking to the existence of an easily available and
releasable pool of drug that elutes within the ﬁrst day (ﬁrst time point)
following arterial implantation, plus a pool of sustained-eluting drug
with a half-life of 28-32 days. Notably, the fraction of drug load that is
sustained-eluting and its half-life of release both decreased with
increasing hole-size (Fig B). Tissue content tracked the ﬁrst order
elution of the sustained-eluting drug pool down to an apparent
plateau level of 0.510.03 ng/mg (Fig C) and was not statistically
different for any of the hole sizes evaluated (15, 20, and 25 mm).
CONCLUSIONS Though drug in tissue from DFS with hole-sizes of 15
to 25mm were bioequivalent, hole-size emerged as a design parameter
for predictably titrating local tissue retention of DFS eluted drug.
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BACKGROUND The advent of bioresorbable scaffolds is redrawing
attention to accurate device size selection. While signiﬁcant undersizing
often results in incomplete strut apposition (ISA) or underexpansion,
possible impact of oversized stent implantation on arterial wall injury has
not been systematically investigated with drug-eluting stents (DES).
METHODS To evaluate the effect of stent oversizing on acute and
long-term outcomes, serial (baseline and 6-12 months) coronary
angiography and IVUS were performed in 2931 lesions treated with
DES (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343everolimus). The degree of stent oversizing (%SO) to angiographic
reference vessel diameter (RVD) was calculated as (nominal stent
diameter – RVD) / RVD x 100 (%). Post-procedural stent expansion was
calculated by IVUS as minimum stent area divided by the average
reference lumen area. Clinical outcomes including target lesion
revascularization (TLR) and stent thrombosis were followed for 1 year.
RESULTS Overall, smaller pre-procedural RVD was linearly associated
withhigher%SO (r¼-0.670, p<0.001). Signiﬁcant stent oversizing (deﬁned
as%SO>10%)was found in82%of small RVD (<2.75mm)group and33%of
larger RVD (2.75mm) group. The signiﬁcant oversizing group underwent
less post-dilatation (p¼0.002), but achieved greater stent expansion
(p<0.001) and less ISA (p<0.001) without increase of edge dissection after
procedure. When stratiﬁed by vessel size and stent oversizing (no differ-
ence in DES type among the 4 groups, p¼0.525), progressive decreases of
angiographic binary restenosis and TLR rates (left ﬁgure) were found in
favor of larger vessel size and oversized stents. Stent thrombosis was
observed the most in the small RVD with low %SO group compared with
the other subgroups (p¼0.040) (right ﬁgure).
CONCLUSIONS In this pooled data analysis, no negative impact of stent
oversizing was documented with respect to procedural and long-term
clinical outcomes. Clinical adverse events appeared to be primarily
related to vessel size itself, rather than the selection of a stent larger than
the vessel size. In particular, small vessels treated with a smaller stent
were associated with greater adverse events, suggesting that aggressive
selection of larger stents with appropriate attention to edge effects may
optimize long-term outcomes even in DES implantation.
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onary stent implantation is associated with higher risk for bleeding.
Second-generation drug-eluting stents (G2-DES), cobalt-chromium
everolimus-eluting stent (CoCr-EES) in particular, are reported to
have lower risk for stent thrombosis (ST) compared with ﬁrst gener-
ation DES or bare-metal stents. Therefore, the optimal DAPT duration
after CoCr-EES implantation could be shorter than 6-12 months
currently recommended in the guidelines. However, there has been
no prospective study evaluating DAPT duration shorter than 6 months
after CoCr-EES implantation.
METHODS STOPDAPT study is a prospective multicenter single-arm
registry enrolling patients who agreed to follow the 3-month DAPT
protocol (discontinuation of clopidogrel at 2- to 4-month and aspirin
monotherapy thereafter) after successful CoCr-EES implantation. The
primary endpoint was a composite of cardiovascular (CV) death,
myocardial infarction (MI), stroke, deﬁnite ST and TIMI major/minor
bleeding at 1-year. As a historical comparison group, we selected the
CoCr-EES group in the RESET trial comparing CoCr-EES with sirolimus-
eluting stent conducted in 2010, where nearly 90% of patients had
continued DAPT at 1-year. With the 6.6% of performance goal based on
the event rate of 4.4% in the RESET trial, a total of 1500 patients would
yield 95% power at a level of one-sided type 1 error of 0.025.
RESULTS Between September 2012 and October 2013, a total of 1525
patients were enrolled in the study from 58 participating centers across
Japan, and 1-year follow-up was completed in 1519 patients (99.6%).
Thienopyridine was discontinued within 4-month in 1444 patients
(94.7%). The event rates beyond 3-month were very low (CV death:
0.5%, MI: 0.1%, deﬁnite/probable ST: 0%, stroke: 0.7%, and TIMI ma-
jor/minor bleeding: 0.8%). Cumulative 1-year incidence of the primary
endpoint was 2.8% (Upper 97.5% conﬁdence interval [CI] 3.6%), which
was lower than the pre-deﬁned performance goal of 6.6% (P<0.0001).
Compared to CoCr-EES group in the RESET trial, cumulative incidence
of the primary endpoint tended to be lower in the STOPDAPT than in
the RESET (2.8% versus 4.0%, P¼0.06) and adjusted hazard ratio was
0.64 (95%CI 0.42-0.95, P¼0.03). The cumulative incidence of deﬁnite/
probable ST was lower in the STOPDAPT than in the RESET (0 patient
[0%] versus 5 patients [0.3%], P¼0.03).
CONCLUSIONS Stopping DAPT at 3-month after CoCr-EES implanta-
tion was at least as safe as the prolonged DAPT regimen adopted in the
previous randomized trial.
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in ST elevated myocardial infarction. The prevalence of very elderly
patients (> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The beneﬁt of the new generation
drug-eluting stents over bare metal stents in terms of safety and efﬁ-
cacy is unknown for this important subgroup of patients in this setting.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,132 (68.2%) treated
with BMS and 994 (31.8%) treated with new generation DES. After exclu-
sion of patients presenting with cardiogenic shock or requiring cardiac
surgery for mechanical complications (14%) a propensity score matching
was performed yielding two comparable groups of 580 patients each with
well- balanced baseline clinical or angiographic characteristics. Outcomes
at 12 months were: cardiac death and MI 10.2% with BMS and 5.2% with
DES (p¼0.01), TLR was 3.8% with BMS and 1.5% with DES (p¼0.04), deﬁ-
nite or probable thrombosis 4.3% with BMS and 2.4% with DES (p¼0.06),
deﬁnite thrombosis 3.7% with BMS and 1.3% with DES (p¼0.03) and
bleeding BARC > 2 0.7% with BMS and 1.2% with DES (p¼0.3).
CONCLUSIONS In this registry of patients over 75 years undergoing
primary angioplasty, most were treated with BMS. After propensity
score matching clinical outcomes were signiﬁcantly better in those
treated with new DES without signiﬁcant increase in severe bleeding
events in follow up.
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BACKGROUND Percutaneous intervention of distal bifurcation un-
protected left main coronary arteries (UPLMCA) are technically
demanding with less favorable outcomes. The optimal treatment
strategy to improve long-term outcomes is uncertain.
METHODS Studies comparing simple approach (provisional stenting)
versus complex stenting (elective two stent technique) were consid-
ered for inclusion. A search strategy using Medline, Embase, Cochrane
database and the proceedings of the international meetings were
included. Information about study design, inclusion criteria and
sample characteristics were extracted. Meta-analysis of pooled event
rates was compared between these two stenting approaches.
RESULTS 16 studies including 5978 patients who were treated with
simple versus complex bifurcation stenting for UPLMCA bifurcations
were analyzed. There were no differences in the rates of myocardial
infarction (OR 0.81, CI 0.15-4.2), stent thrombosis (OR 0.8, CI 0.2-1.7),
target vessel revascularization (OR 0.4, CI 0.6-2.7) or mortality (OR
0.92, CI 0.3-2.8) between simple versus complex stenting approaches
at 1 year. However, at 5 years of follow-up there was a signiﬁcant
difference in the rates of target vessel revascularization (OR 0.4, CI
0.3-0.7, p¼0.001) favoring the simple approach. There was no differ-
ence in the mortality (OR 0.94, CI 0.75-1.19), stent thrombosis (OR
0.83, 0.32-2.1) or myocardial infarction (OR 1.16, CI 0.7-1.7) using
either approach at 5 years of follow-up.
CONCLUSIONS Percutaneous intervention for UPLMCA should favor
a simple approach over complex approach to optimize long-term
outcomes.
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BACKGROUND Stent fracture (SF) after drug-eluting stent implanta-
tion has been reported to be associated with in-stent restenosis (ISR),
